Table 1.
Study ID | Authors | Publication year | Study type | Pain type | Intervention | Sample size | Mean age | Country | Included for MA | Included for NMA |
---|---|---|---|---|---|---|---|---|---|---|
1 | Weizman et al. | 2018 | P–C, RCT | Chronic-pain | THC | 17 | 33.3 | Israel | No | No |
2 | Krebs et al. | 2018 | RCT | Back, Arthritis, Chronic-pain | Opioid | 240 | 56.8 | USA | No | No |
3 | AbdelHafeez et al. | 2019 | Double-blind, P–C, RCT | Chronic-pain | Gabapentin | 60 | 32.7 | UK | Yes | Yes |
4 | Bushey et al. | 2021 | RCT | Chronic-pain | Opioid | 241 | 37 | USA | No | No |
5 | Bruehl et al. | 2021 | Double-blind, P–C, RCT, Crossover | Low-back, Chronic-pain | Morphine + Naloxone | 191 | 36.5 | USA | No | No |
6 | Worley et al. | 2015 | RCT | Chronic-pain | Buprenorphine/Naloxone | 149 | USA | No | No | |
7 | Dindo et al. | 2018 | Single-blinded, RCT | Postsurgical, Chronic-pain | ACT | 76 | 62.2 | USA | No | No |
8 | Hruschak et al. | 2019 | Single-blinded, RCT | Chronic-pain | IPGT | 30 | 53.9 | USA | No | No |
9 | Azevedo et al. | 2013 | Chronic-pain | Opioid | 2213 | 45 | Portugal | No | No | |
10 | Gudin et al. | 2020 | Open-label, P–C, Uncontrolled | Low-back, Noncancer, Chronic-pain | NKTR-181 | 402 | 52 | USA | No | No |
11 | Stahl et al. | 2019 | RCT | Low-back, Chronic-pain | Venlafaxine | 209 | 69.6 | USA | No | No |
12 | Schliessbach et al. | 2018 | Double-blind, P–C, RCT | Low-back, Chronic-pain | Imipramine | 50 | 54.4 | Switzerland | No | No |
13 | Mohamed et al. | 2016 | Double-blind, RCT | PostsurgicalNeuropathic, Cancer, Chronic-pain | Morphine | 90 | 50.43 | Egypt | No | No |
14 | Schliessbach et al. | 2018 | P–C, RCT | Low-back, Chronic-pain | Oxycodone + Imipramine + Clobazam | 98 | 55 | Switzerland | No | Yes |
15 | Hermans et al. | Double-blind, P–C, RCT, Crossover | Arthritis, Chronic-pain | Naloxone | 31 | 39.8 | Belgium | No | No | |
16 | Todorov et al. | 2005 | Chronic-pain | Gabapentin + Tiagabine | 91 | 42 | USA | No | Yes | |
17 | Sadatsune et al. | Double-blind, P–C, RCT | Chronic-pain | Gabapentin | 40 | 51.5 | Brazil | No | No | |
18 | Edwards et al. | 2016 | RCT | Back, Chronic-pain | Opioid | 31 | 49 | USA | No | No |
19 | Katz et al. | 2011 | Double-blind, P–C, RCT | Low-back, Chronic-pain | Naproxen + Tanezumab | 129 | 52.1 | USA | No | No |
20 | Hayek et al. | 2021 | Double-blind, RCT, Crossover | Chronic-pain | Opioid + Bupivacaine | 16 | 63.1 | USA | No | No |
21 | Schliessbach et al. | 2017 | Double-blind, P–C, Crossover | Back, Chronic-pain | Clobazam | 49 | 54.3 | Switzerland | No | Yes |
22 | Bruehl et al. | 2004 | Double-blind, P–C, RCT, Crossover | Low-back, Noncancer, Chronic-pain | Opioid | 28 | 37.3 | USA | No | No |
23 | Kim et al. | 2018 | Double-blind, RCT | Postsurgical, Chronic-pain | Nefopam | 58 | 40 | South korea | No | No |
24 | Eisenach et al. | 2010 | Double-blind, P–C, RCT, Crossover | Chronic-pain | Ketorolac | 15 | 44 | No | No | |
25 | Rauck et al. | 2014 | Single-blinded, RCT, Crossover | Chronic-pain | Adenosine/Clonidine | 22 | 44 | USA | No | No |
26 | Buchheit et al. | 2019 | Double-blind, P–C, RCT | Postsurgical, Chronic-pain | Valproate | 128 | 57 | USA | No | No |
27 | Papadokostakis et al. | 2005 | Back, Chronic-pain | Calcitonin | 110 | 65 | Greece | No | No | |
28 | Gould et al. | 2020 | Double-blind, 4-arm, RCT | Back, Chronic-pain | Desipramine | 141 | 51.5 | USA | No | Yes |
29 | Schnitzer et al. | 2016 | Double-blind, P–C, RCT | Back, Chronic-pain | D-cycloserine | 41 | 53.2 | USA | No | No |
30 | Nenke et al. | 2015 | Double-blind, P–C, RCT, Crossover | Low-back, Noncancer, Chronic-pain | Hydrocortisone | 26 | 71 | Australia | Yes | Yes |
31 | Sopata et al. | 2015 | Double-blind, P–C, RCT | Chronic-pain | Opioid | 100 | 62.1 | Poland | No | No |
32 | Kendall et al. | Double-blind, P–C, RCT | Postsurgical, Chronic-pain | Lidocaine | 148 | 48 | usa | No | No | |
33 | Hongo et al. | 2015 | RCT | Back, Chronic-pain | Risedronate + Elcatonin | 45 | 70.9 | Japan | No | No |
34 | Amr and Yousef | 2010 | Double-blind, RCT | Postsurgical, Chronic-pain | Venlafaxine + Gabapentin | 150 | 45 | Egypt | No | No |
35 | Pedersen et al. | 2014 | Double-blind, RCT | Chronic-pain | Codeine + Paracetamol | 58 | 49 | Norway | No | No |
36 | Choi et al. | 2016 | Double-blind, RCT | Postsurgical, Chronic-pain | Lidocaine | 90 | 34 | Korea | No | No |
37 | Bruehl et al. | 2014 | P–C, RCT | Back, Chronic-pain | Morphine + Naloxone | 50 | 36.9 | USA | Yes | Yes |
38 | Chrubasik et al. | 2010 | Double-blind, P–C, RCT | Chronic-pain | Capsicum | 130 | 48.9 | Germany | No | No |
39 | Schliessbach et al. | 2017 | Double-blind, P–C, RCT, Crossover | Back, Chronic-pain | Oxycodone | 50 | 55 | Switzerland | No | Yes |
40 | Bruehl and Chung | 2006 | Double-blind, P–C, RCT, Crossover | Low-back, Chronic-pain | Naloxone | 119 | 35.1 | USA | No | No |
41 | Bruehl et al. | 2013 | Double-blind, P–C, RCT, Crossover | Low-back, Chronic-pain | Naloxone + Morphine | 76 | 37.9 | USA | No | No |
42 | Burns et al. | 2017 | Double-blind, P–C, RCT | Low-back, Chronic-pain | Naloxone + Morphine | 89 | 36.9 | USA | No | No |
43 | Eker et al. | 2016 | Double-blind, RCT | Knee, Arthritis, Chronic-pain | Lidocaine | 52 | 65.15 | Turkey | Yes | Yes |
44 | Kim et al. | 2015 | Double-blind, RCT | Cancer, Chronic-pain | Opioid | 49 | 62 | Korea | No | No |
45 | Kimos et al. | 2007 | Double-blind, P–C, RCT | Chronic-pain | Gabapentin | 50 | 33.58 | Canada | Yes | Yes |
46 | Narang et al. | 2008 | Double-blind, P–C, RCT, Crossover | Chronic-pain | Opioid | 30 | 43.5 | USA | No | No |
47 | Peyton et al. | 2017 | P–C, RCT | Postsurgical, Chronic-pain | Ketamine | 80 | 55.3 | Australia | No | No |
48 | Katz et al. | 2005 | P–C, RCT, Crossover | Low-back, Chronic-pain | Bupropion | 60 | 49.8 | Yes | Yes | |
49 | Hashmi et al. | 2012 | Double-blind, P–C, RCT | Back, Chronic-pain | Lidocaine | 30 | 51.36 | USA | No | No |
50 | Shimoyama et al. | 2014 | Double-blind, P–C, RCT, Crossover | Cancer, Chronic-pain | Fentanyl | 51 | 59.1 | Japan | No | No |
51 | Wreje and Brorsson | 1995 | RCT | Chronic-pain | Sterile water | 117 | > = 25 | Sweden | No | No |
52 | Han et al. | 2016 | Double-blind, P–C, RCT | Neuropathic, Chronic-pain | BTX-A | 40 | 53.1 | korea | Yes | Yes |
53 | Rauck et al. | 2014 | Double-blind, P–C, RCT | Chronic-pain | Hydrocodone | 510 | 50.4 | USA | No | No |
54 | Kim et al. | 2010 | Double-blind, P–C, RCT | Postsurgical, Chronic-pain | Pregabalin | 94 | 39 | Korea | No | No |
55 | Lee et al. | 2019 | RCT | Chronic-pain | BTX-A | 60 | 50.9 | Korea | No | No |
56 | Rashiq et al. | 2003 | Double-blind, P–C, RCT, Crossover | Low-back, Chronic-pain | Fentanyl | 28 | 54 | Yes | Yes | |
57 | Kang et al. | 2020 | Double-blind, P–C, RCT | Postsurgical, Chronic-pain | Ketamine | 168 | 50.8 | korea | No | No |
58 | Lipton et al. | 2021 | P–C, RCT | Chronic-pain | Erenumab | 955 | 41.1 | Canada-13* | No | No |
59 | Williamson et al. | 2014 | P–C, RCT | Low-back, Knee, Arthritis, Chronic-pain | Duloxetine | 780 | 63.2 | Canada | No | No |
60 | Guo et al. | 2020 | RCT | Low-back, Chronic-pain | Celecoxib Eperisone | 150 | 36 | China | No | No |
61 | Damjanov et al. | 2018 | Double-blind, P–C, RCT | Chronic-pain | ACS | 32 | 59 | No | No | |
62 | Abd-Elshafy et al. | 2019 | Double-blind, RCT | Postsurgical, Chronic-pain | Bupivacaine | 60 | 35 | Egypt | No | Yes |
63 | Levesque et al. | 2021 | Double-blind, RCT | Chronic-pain | BTX + Ropivacaïne | 80 | 53.1 | No | No | |
64 | Maher et al. | 2018 | P–C, RCT | Chronic-pain | Ketamine | 79 | 50.32 | USA | No | No |
65 | Barry et al. | 2019 | RCT | Back, Chronic-pain | Methadone | 40 | 37.7 | USA | No | No |
66 | Shokeir and Mousa | 2015 | Double-blind, P–C, RCT | Chronic-pain | Bupivacaine | 60 | 32.8 | Egypt | Yes | Yes |
67 | Scudds et al. | 1995 | Double-blind, P–C, RCT | Chronic-pain | Lidocaine | 61 | 46.1 | Canada | No | No |
68 | Gimbel et al. | 2016 | Double-blind, P–C, RCT | Low-back, Chronic-pain | Buccal buprenorphine | 510 | 52.8 | USA | No | No |
69 | Matsuoka et al. | 2019 | P–C, RCT | Neuropathic, Cancer, Chronic-pain | Duloxetine | 70 | 64.7 | Japan | No | No |
70 | Yurekli et al. | 2008 | Double-blind, P–C, RCT | Chronic-pain | Sodium valproate | 70 | 40 | Turkey | Yes | Yes |
71 | Maarrawi et al. | 2018 | Double-blind, P–C, RCT | Chronic-pain | Amitriptyline | 112 | 43.54 | Lebanon | Yes | Yes |
72 | Li et al. | 2018 | Double-blind, RCT | Postsurgical, Chronic-pain | Ropivacaine + Dexamethasone | 52 | 62 | China | No | No |
73 | Almog et al. | 2020 | Double-blind, 3-arm, RCT, Crossover | Chronic-pain | THC | 27 | 48.3 | Israel | No | No |
74 | Wylde et al. | 2015 | Double-blind, RCT | Postsurgical, Knee, Chronic-pain | Bupivacaine | 273 | 66 | UK | No | No |
75 | Matsukawa et al. | 2020 | RCT | Chronic-pain | Cernitin + Tadalafil | 100 | 65.9 | Japan | No | No |
76 | Haddad et al. | 2018 | Double-blind, P–C, RCT, Crossover | Chronic-pain | Apomorphine | 35 | 56.2 | Israel | No | No |
77 | de Vries et al. | 2016 | Double-blind, P–C, RCT | Postsurgical, Chronic-pain | THC | 65 | 52.2 | Netherlands | Yes | Yes |
78 | Urquhart et al. | 2018 | Double-blind, RCT | Low-back, Chronic-pain | Amitriptyline | 146 | 53.5 | Australia | No | Yes |
79 | Lichtman et al. | 2018 | Double-blind, P–C, RCT | Cancer, Chronic-pain | Nabiximols | 397 | 59.2 | Belgium-12* | No | No |
80 | Schiphorst et al. | 2014 | Trible-Blind, P–C, RCT | Low-back, Chronic-pain | Acetaminophen/Tramadol | 50 | 42 | Netherlands | No | No |
81 | Cardenas et al. | 2002 | RCT | Chronic-pain | Amitriptyline | 84 | 41 | USA | Yes | Yes |
82 | Arnold et al. | 2012 | Double-blind, P–C, RCT | Chronic-pain | Milnacipran | 1025 | 49.1 | USA | No | No |
83 | Wasan et al. | 2005 | Double-blind, P–C, RCT, Crossover | Low-back, Chronic-pain | Morphine | 20 | 44.2 | USA | No | No |
84 | Baron et al. | 2014 | Double-blind, RCT | Neuropathic, Low-back, Chronic-pain | Tapentadol/Pregabalin | 445 | 56.3 | Germany | No | No |
85 | Portenoy et al. | 2007 | Double-blind, P–C, RCT | Low-back, Chronic-pain | Fentanyl | 77 | 48.9 | USA | No | No |
86 | Likar et al. | 1997 | Double-blind, RCT, Crossover | Arthritis, Chronic-pain | Morphine | 21 | 68 | Austria | No | No |
87 | Schwartzman et al. | 2009 | Double-blind, P–C, RCT | Chronic-pain | Ketamine | 20 | 38 | USA | Yes | Yes |
88 | Chu et al. | 2012 | Double-blind, P–C, RCT | Back, Chronic-pain | Morphine | 139 | 44 | USA | Yes | Yes |
89 | Sandrini et al. | 2011 | Double-blind, P–C, RCT | Chronic-pain | BoNTA | 56 | 48.5 | USA | No | No |
90 | Mahowald et al. | 2009 | Single-blinded, P–C, RCT | Arthritis, Chronic-pain | BoNTA | 40 | > = 48 | USA | Yes | Yes |
91 | Loftus et al. | 2010 | Double-blind, P–C, RCT | Back, Chronic-pain | Ketamine | 102 | 51.7 | Lebanon /USA | Yes | Yes |
92 | Lehmann et al. | 1997 | P–C, RCT | Postsurgical, Chronic-pain | Fentanyl | 29 | 44.15 | USA | No | No |
93 | Kahlenberg et al. | 2017 | P–C, RCT | Chronic-pain | Celecoxib | 98 | 34.2 | USA | Yes | Yes |
94 | Silberstein et al. | 2009 | Double-blind, P–C, RCT | Chronic-pain | Topiramate | 306 | 38.2 | USA | No | No |
95 | Burgher et al. | 2011 | Double-blind, RCT | Low-back, Chronic-pain | Lidocaine | 26 | 44.1 | USA | No | No |
96 | McCleane | 1999 | Double-blind, P–C, RCT, Crossover | Neuropathic, Chronic-pain | Phenytoin | 20 | 40 | Ireland | Yes | Yes |
97 | Naliboff et al. | 2011 | 2-arm, RCT | Chronic-pain | Opioid | 135 | 52.7 | USA | No | No |
98 | Booth et al. | 2017 | P–C, RCT | Postsurgical, Chronic-pain | Morphine | 74 | 28 | USA | No | Yes |
99 | Lee et al. | 2006 | Single-blinded, RCT | Chronic-pain | Rowatinex/Ibuprofen | 50 | 44.2 | Korea | No | No |
100 | Levendoglu et al. | 2004 | Double-blind, P–C, RCT, Crossover | Neuropathic, Chronic-pain | Gabapentin | 20 | 35.9 | Turkey | Yes | Yes |
101 | Yousef and Alzeftawy | 2018 | Double-blind, RCT | Chronic-pain | Opioid | 100 | 53.44 | Egypt | No | Yes |
102 | Yelland et al. | 2009 | Double-blind, P–C, RCT, Crossover | Neuropathic, Chronic-pain | Gabapentin | 73 | 57.8 | Australia | No | No |
103 | Yucel et al. | 2004 | Double-blind, P–C, RCT | Neuropathic, Chronic-pain | Venlafaxine | 55 | 48.94 | Turkey | No | No |
104 | Hudson et al. | 2021 | Double-blind, P–C, RCT | Knee, Arthritis, Chronic-pain | Nortriptyline | 205 | 64.4 | New Zealand | Yes | Yes |
105 | Rauck et al. | 2006 | Double-blind, P–C, RCT | Chronic-pain | Ziconotide | 220 | 52.5 | USA | No | No |
106 | Sandner-Kiesling et al. | 2010 | Double-blind | Noncancer, Chronic-pain | Naloxone + Oxycodone | 379 | 56.2 | Austria/Germany | No | No |
107 | Wang et al. | 2017 | RCT | Chronic-pain | Diosmin | 300 | 41 | China | No | Yes |
108 | Hawley et al. | 2020 | Double-blind, P–C, RCT, Crossover | Cancer, Chronic-pain | Lidocaine | 25 | 53.76 | Canada | No | No |
109 | Mathieson et al. | 2017 | Double-blind, P–C, RCT | Chronic-pain | Pregabalin | 209 | 66 | Australia | No | No |
110 | Wetzel et al. | 2015 | Double-blind, P–C, RCT, Crossover | Low-back, Noncancer, Chronic-pain | Nonopioid analgesic drugs | 36 | 55 | Austria | No | No |
111 | Khan et al. | 2019 | P–C, RCT | PostsurgicalNeuropathic, Cancer, Chronic-pain | Lidocaine + Pregabalin | 100 | 55.2 | Canada | No | No |
112 | Clarke et al. | 112 | Double-blind, RCT | Postsurgical, Chronic-pain | Gabapentin | 126 | 58.9 | Canada | Yes | Yes |
113 | Ma et al. | 113 | Double-blind, P–C, RCT | Chronic-pain | Oxycodone | 116 | 58.2 | China | Yes | Yes |
114 | J. H. Lee and C. S. Lee | 114 | Double-blind, P–C, RCT | Low-back, Chronic-pain | TA-ER | 245 | 59.9 | Korea | No | No |
115 | Imamura et al. | 2016 | Trible-Blind, RCT | Low-back, Chronic-pain | Lidocaine | 378 | 48.26 | Brazil | No | No |
116 | Baron et al. | 2015 | RCT | Neuropathic, Low-back, Chronic-pain | Tapentadol | 258 | 58.1 | Germany | No | No |
117 | Kim et al. | 2017 | Double-blind, RCT | Postsurgical, Cancer, Chronic-pain | Lidocaine + Magnesium | 126 | 48.7 | Korea | Yes | Yes |
118 | Iwamura et al. | 2015 | RCT | Chronic-pain | Eviprostat | 100 | 50.1 | Japan | No | No |
119 | Zhang et al. | 2021 | Double-blind, P–C, RCT | Chronic-pain | Ningmitai | 120 | 33.7 | China | No | No |
Canada-13*: “Canada-13” was used as the group of 13 countries: “Canada, Austria, Belgium, Czech Republic, Finland, Germany, Poland, Slovakia, Sweden, the United Kingdom, Turkey, the Netherlands and USA”.
Belgium-12*: “Belgium-12” was used as the group of 12 countries: “Belgium, Bulgaria, Czechia, Germany, Hungary, Latvia, Lithuania, Poland, Puerto Rico, Romania, United Kingdom, United States”.